138326-68-8

Basic information

• Product Name: S-Cyclopropylglycine Methyl ester hydrochloride
• Synonyms: S-Cyclopropylglycine Methyl ester hydrochloride;L-Cyclopropylglycine methyl ester hydrochloride;Methyl (S)-a-amino-cyclopropaneacetate HCl;(S)-Methyl 2-amino-2-cyclopropylacetate hydrochloride;Methyl (2S)-amino(cyclopropyl)-acetate hydrochloride;S-2-Cyclopropylglycine methyl ester hydrochloride
• CAS NO: 138326-68-8
• Molecular Formula: C₆H₁₁NO₂*ClH
• Molecular Weight: 165.62
• EINECS: -0
• Mol File: 138326-68-8.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: S-Cyclopropylglycine Methyl ester hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: S-Cyclopropylglycine Methyl ester hydrochloride(138326-68-8)
• EPA Substance Registry System: S-Cyclopropylglycine Methyl ester hydrochloride(138326-68-8)

Safety Data

• Hazardous Substances Data: 138326-68-8(Hazardous Substances Data)

Usage

General Description

S-Cyclopropylglycine Methyl ester hydrochloride is a synthetic chemical compound that is commonly used in pharmaceutical research and development. It is a derivative of the amino acid glycine, and the addition of a cyclopropyl group and a methyl ester to the glycine molecule enhances its pharmacological properties. S-Cyclopropylglycine Methyl ester hydrochloride has potential applications as a building block in the synthesis of biologically active compounds and as a precursor in the development of new drugs. The hydrochloride salt form of S-Cyclopropylglycine Methyl ester is commonly used for its improved solubility and stability, making it a valuable tool in the pharmaceutical industry. Additionally, this compound may have potential therapeutic and pharmaceutical applications due to its ability to modulate neurotransmission and synaptic function in the central nervous system. Overall, S-Cyclopropylglycine Methyl ester hydrochloride is an important chemical in pharmaceutical research due to its versatile properties and potential medical applications.

Upstream product

• 49606-99-7 (S)-2-amino-2-cyclopropylacetic acid 
• 75-36-5 acetyl chloride 
• 77-76-9 2,2-dimethoxy-propane 
• 155976-13-9 (2S)-2-[[(tert-butoxy)carbonyl]amino]-2-cyclopropylacetic acid 
• 67-56-1 methanol 

Downstream Products

• 1093191-55-9 (S)-cyclopropyl-(4-(4-morpholin-4-ylmethylphenylethynyl)benzoylamino)acetic acid methyl ester 
• 874336-34-2 C₂₆H₃₄N₂O₅ 
• 874336-36-4 (S)-2-(((R)-2-(2-(3-(((benzyloxy)carbonyl)amino)propyl)phenoxy)-propyl)(tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid 
• 874336-40-0 C₅₀H₆₁FN₄O₉ 
• 1351469-17-4 C₄₂H₅₅FN₄O₇ 
• 874336-42-2 (R)-2-((R)-2-((S)-2-(((R)-2-(2-(3-aminopropyl)phenoxy)propyl)-amino)-2-cyclopropyl-N-methylacetamido)propanamido)-3-(4-fluorophenyl)propanoic acid 
• 874336-35-3 C₃₁H₄₂N₂O₇ 
• 874336-43-3 C₃₀H₃₉FN₄O₄*ClH 
• 842131-33-3 ulimorelin 
• 1093191-57-1 N-((S)-cyclopropyl(hydroxycarbamoyl)methyl)-4-(4-morpholin-4-ylmethylphenylethynyl)benzamide trifluoroacetate 
• 1047665-90-6 C₂₆H₃₃FN₂O₅ 

Relevant articles and documents

Macrocyclic Modulators of the Ghrelin Receptor

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from Hit to Clinic

High-throughput screening of Tranzyme Phar-ma's proprietary macrocycle library using the aequorin Ca2+-bioluminescence assay against the human ghrelin receptor (GRLN) led to the discovery of novel agonists against this G-protein coupled receptor. Early hits such as 1 (Ki = 86 nM, EC50 = 134 nM) though potent in vitro displayed poor pharmacokinetic properties that required optimization. While such macrocycles are not fully rule-of-five compliant, principally due to their molecular weight and clogP, optimization of their pharmacokinetic properties proved feasible largely through conformational rigidification. Extensive SAR led to the identification of 2 (Ki = 16 nM, EC50 = 29 nM), also known as ulimorelin or TZP-101, which has progressed to phase III human clinical trials for the treatment of postoperative ileus. X-ray structure and detailed NMR studies indicated a rigid peptidomimetic portion in 2 that is best defined as a nonideal type-I′ β-turn. Compound 2 is 24% orally bioavailable in both rats and monkeys. Despite its potency, in vitro and in gastric emptying studies, 2 did not induce growth hormone (GH) release in rats, thus demarcating the GH versus GI pharmacology of GRLN. (Figure presented)

NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS

Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R6 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.